CSL: Shares Will Recover As Seqirus Headwinds Ease After Recent Pullback

Analysts have trimmed their price target on CSL slightly, from about A$230 to A$225, reflecting tempered expectations for Seqirus amid weaker U.S. vaccination trends and the indefinite deferral of the planned vaccine business demerger, even as they note that the recent share price correction has opened a more attractive entry point.

Analyst Commentary

Analyst views on CSL have turned more constructive following the share price pullback, even as earnings expectations have been nudged lower to reflect the softer outlook for Seqirus.

Bullish Takeaways

• Bullish analysts argue that the recent share price correction has overshot fundamentals, creating a more attractive entry point relative to long term growth prospects.
• The move to a Buy rating, despite a slightly reduced price target, is framed as a valuation call, with upside seen as earnings normalize and sentiment around Seqirus stabilizes.
• Long term growth in CSL’s core businesses, including plasma and broader specialty therapies, is viewed as intact, supporting a premium multiple once near term headwinds abate.
• The indefinite deferral of the vaccine demerger is now seen by some as largely priced in, which limits further downside from structural uncertainty.

Bearish Takeaways

• Bearish analysts highlight that weaker U.S. vaccination uptake at Seqirus is pressuring near term revenue and margin assumptions, which is used to justify the lower price target.
• The downgrade at the annual general meeting is viewed as a signal that execution risk around Seqirus is higher than previously expected, particularly if vaccination trends do not rebound.
• The decision to defer the vaccine demerger introduces strategic uncertainty, and some caution that it may constrain management’s ability to unlock value in the near term.
• With guidance reset lower, there is concern that further earnings downgrades could follow if macro or demand conditions deteriorate, which could limit multiple expansion in the short run.

What's in the News

• CSL lowered its financial year 2026 revenue growth guidance to 2% to 3%, down from 4% to 5%, citing softer performance expectations in the first half of the year (Corporate Guidance).
• CSL appointed Chief Strategy Officer Ken Lim as Chief Financial Officer effective 7 October 2025, with current CFO Joy Linton to support a transition period before retiring (Executive Changes).
• CSL entered a major strategic collaboration with VarmX to fund and support global Phase 3 development, manufacturing, and pre-launch activities for VMX-C001, and secured an exclusive option to acquire VarmX for up to approximately USD 2.2 billion in upfront, milestone, and sales-based payments (Strategic Alliances).

Valuation Changes

• Fair Value Estimate, eased slightly to A$244.20 from A$246.96, implying a modest reduction in long term intrinsic value assumptions.
• Discount Rate, edged up marginally to 6.99% from 6.96%, reflecting a small increase in the required return applied to future cash flows.
• Revenue Growth, ticked up fractionally to 4.22% from 4.21%, signaling a near unchanged but slightly more optimistic top line outlook.
• Net Profit Margin, dipped marginally to 21.62% from 21.64%, indicating a very small reduction in expected profitability over the forecast period.
• Future P/E, eased slightly to 25.0x from 25.0x previously, pointing to a near unchanged valuation multiple applied to forward earnings.